Keyword: Dimension Therapeutics
In nine years, Ultragenyx grew from two employees to 700, striking partnerships, jumping into gene therapy through its acquisition of Dimension Therapeutics and getting two rare disease drugs to market.
Ultragenyx is putting up $138 million in cash to wrestle gene therapy biotech Dimension away from its first suitor.
Nightstar will complete a phase 3 trial of its choroideremia gene therapy and advance two other eye disease candidates through early-stage studies.
The takeover will see Regenxbio pay about $86 million to add two of early-stage gene therapies to its pipeline.